Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody Fragment Fab to integrin alpha 2b + beta 3. Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets. The drug is designed for the treatment of patients undergoing percutaneous coronary interventions.
Integrin lpha 2b beta 3
Fab - G1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, ICC and most other immunological methods.
Tested positive against native human antigen.
Immunoglobulin G1, anti- (human integrin alpha IIb beta3) Fab fragment (human-mouse monoclonal C4G1 γ1-chain), disulfide with human-mouse monoclonal C4G1 kappa-chain.
Predicted N terminal
H chain: QVQLVQS; L chain: DIQMTQT
Purity >95% by SDS-PAGE.
4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
The integrins are a family of more than 23 heterodimeric transmembrane proteins that mediate cell-cell adhesions as well as cell-substratum adhesions and signal transduction processes. Integrins are heterodimers consisting of noncovalently associated alpha and beta subunits. CD61 non-covalently associates with CD41 (alpha Ilb integrin) and is expressed by megakaryocytes and platelets. The CD61/CD41 complex acts as a receptor for such adhesive ligands as fibronectin, fibrinogen and von Willebrand factor during platelet stimulation.
cell adhesion molecule binding; identical protein binding; integrin binding; platelet-derived growth factor receptor binding; protein binding; protein disulfide isomerase activity; receptor activity; vascular endothelial growth factor receptor 2 binding;